Simonetta Mocci - Researcher Profile

Publications

2 shown

Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC

Roy S. Herbst , Giuseppe Giaccone , Filippo de Marinis +19 more

Atezolizumab treatment resulted in significantly longer overall survival than platinum-based chemotherapy among patients with NSCLC with high PD-L1 expression, regardless of his...

2020 New England Journal of Medicine 1580 citations

Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1–Selected Advanced Non–Small-Cell Lung Cancer (BIRCH)

Solange Peters , Scott Gettinger , Melissa L. Johnson +25 more

Purpose BIRCH was designed to examine the efficacy of atezolizumab, a humanized anti–programmed death-ligand 1 (PD-L1) monoclonal antibody, in advanced non–small-cell lung cance...

2017 Journal of Clinical Oncology 412 citations

Frequent Co-Authors

Researcher Info

h-index: 2
Publications: 2
Citations: 1,992
Institution: Kantonsspital St. Gallen

External Links

Google Scholar

Impact Metrics

h-index 2

h-index: Number of publications with at least h citations each.